ADIL Insider Trading (Adial Pharmaceuticals)
Insider Ownership Percentage: 25.26%
Insider Buying (Last 12 Months): $54,400.00
Insider Selling (Last 12 Months): $0.00
Adial Pharmaceuticals Share Price & Price History
Current Price: $1.36
Price Change: ▲ Price Increase of +0.08 (6.25%)
As of 05/16/2022 01:18 PM ET
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.
Adial Pharmaceuticals Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/29/2021||William B. Stilley, III||CEO||Buy||10,000||$2.59||$25,900.00|| |
|11/26/2021||James W. Newman, Jr.||Director||Buy||10,000||$2.85||$28,500.00|| |
|4/6/2021||Bankole A. Johnson||Insider||Sell||150,000||$2.50||$375,000.00||1,055|| |
|3/27/2020||James W. Newman, Jr.||Director||Buy||19,644||$1.28||$25,144.32||15,000|| |
|3/25/2020||William B. Stilley, III||CEO||Buy||12,348||$1.13||$13,953.24||703,285|| |
|12/12/2019||Bankole A. Johnson||Insider||Sell||150,000||$1.00||$150,000.00||351,055|| |
"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
Find Out How This Is Good News
Adial Pharmaceuticals Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/13/2022||Renaissance Technologies LLC||19,958||$40K||0.0%||N/A||0.084%|
|5/13/2022||Empirical Financial Services LLC d.b.a. Empirical Wealth Management||35,000||$70K||0.0%||N/A||0.148%|
|2/17/2022||Goldman Sachs Group Inc.||19,526||$53K||0.0%||N/A||0.094%|
|2/14/2022||Goldman Sachs Group Inc.||19,526||$53K||0.0%||N/A||0.094%|
|2/11/2022||Geode Capital Management LLC||129,327||$0.35M||0.0%||+34.6%||0.623%|
|11/16/2021||Millennium Management LLC||17,049||$73K||0.0%||N/A||0.084%|
|11/12/2021||Oppenheimer & Co. Inc.||38,500||$0.17M||0.0%||+37.5%||0.190%|
|11/12/2021||Geode Capital Management LLC||96,077||$0.41M||0.0%||+8.9%||0.473%|
|11/12/2021||NorthRock Partners LLC||10,000||$43K||0.0%||N/A||0.049%|
|10/29/2021||Commonwealth Equity Services LLC||36,461||$0.16M||0.0%||+25.5%||0.180%|
|9/17/2021||Virtu Financial LLC||31,038||$79K||0.0%||N/A||0.153%|
|8/17/2021||Citadel Advisors LLC||20,198||$52K||0.0%||-72.8%||0.107%|
|8/16/2021||State Street Corp||48,954||$0.13M||0.0%||N/A||0.260%|
|8/13/2021||Northern Trust Corp||21,873||$56K||0.0%||N/A||0.116%|
|8/13/2021||Geode Capital Management LLC||88,246||$0.23M||0.0%||+13.2%||0.469%|
|8/13/2021||Vanguard Group Inc.||585,035||$1.49M||0.0%||+172.4%||3.112%|
|8/11/2021||Commonwealth Equity Services LLC||29,050||$74K||0.0%||+31.7%||0.155%|
|8/3/2021||Oppenheimer & Co. Inc.||28,000||$71K||0.0%||+93.1%||0.152%|
|7/17/2021||Golden Green Inc.||24,700||$63K||0.0%||N/A||0.134%|
|5/14/2021||Dimensional Fund Advisors LP||31,410||$76K||0.0%||+68.8%||0.179%|
|5/12/2021||Rede Wealth LLC||15,000||$36K||0.0%||N/A||0.086%|
|5/10/2021||Oppenheimer & Co. Inc.||14,500||$35K||0.0%||N/A||0.083%|
|5/4/2021||Commonwealth Equity Services LLC||22,050||$53K||0.0%||+107.3%||0.126%|
|4/22/2021||Private Advisor Group LLC||36,650||$89K||0.0%||N/A||0.212%|
|3/8/2021||Dimensional Fund Advisors LP||18,612||$32K||0.0%||N/A||0.129%|
|2/25/2021||Dimensional Fund Advisors LP||18,612||$32K||0.0%||N/A||0.129%|
|2/10/2021||Renaissance Technologies LLC||98,900||$0.17M||0.0%||+6.5%||0.687%|
|12/11/2020||Virtu Financial LLC||18,902||$42K||0.0%||N/A||0.131%|
|8/14/2020||Bank of America Corp DE||150,000||$0.21M||0.0%||N/A||1.115%|
|8/14/2019||Vanguard Group Inc.||293,908||$0.49M||0.0%||-3.2%||2.875%|
|2/14/2019||Two Sigma Investments LP||11,775||$60K||0.0%||N/A||0.180%|
|2/13/2019||Geode Capital Management LLC||13,581||$69K||0.0%||N/A||0.207%|
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Adial Pharmaceuticals?
Who are the major institutional investors of Adial Pharmaceuticals?
Which institutional investors are buying Adial Pharmaceuticals stock?
Within the last quarter, ADIL stock was acquired by institutional investors including:
- Empirical Financial Services LLC d.b.a. Empirical Wealth Management
- Renaissance Technologies LLC
Within the previous year, these company insiders have bought Adial Pharmaceuticals stock:
Learn More investors buying Adial Pharmaceuticals stock.
- Bankole A Johnson (Insider)
- James W Jr Newman (Director)